Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At The American Association For Cancer Research Meeting

Peregrine's Anti-Angiogenesis 2C3 Anti-VEGF Antibody Presented at American Association For Cancer Research Meeting

Peregrine Reports Voting Results Of Annual Meeting

Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At Angiogenesis Conference

Targeted Delivery of Tissue Factor Research Published in 'Cancer Research'

Peregrine Researchers Receive Grant From Phillip Morris For Lung Cancer Research

Tumor Necrosis Therapy Receives Marketing Approval for Advanced Lung Cancer In The People's Republic of China

Peregrine's Vascular Targeting Agents Presented at American Association of Cancer Research Annual Meeting

Peregrine's Vascular Targeting Agent Inhibits Growth of Breast Cancer Tumor Metastases by 50 Percent in Pre-Clinical Studies

Peregrine Maintains Listing On Russell 2000 And 3000 IndexesR